Evidence map›Paper›PMID 29734948›Full record

ArticleBMC pediatrics2018

Inhaled corticosteroids in ventilated preterm neonates: a non-randomized dose-ranging study.

Kamini Raghuram, Michael Dunn, Krista Jangaard, Maureen Reilly, Elizabeth Asztalos, Edmond Kelly, Michael Vincer, Vibhuti Shah

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03503994 (A Dose-Ranging Study to Assess the Effect of Inhaled Corticosteroids in Ventilated Preterm Neonates), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03503994 nacompletednot on this map

A Dose-Ranging Study to Assess the Effect of Inhaled Corticosteroids in Ventilated Preterm Neonates

TypeinterventionalSponsorMount Sinai Hospital, CanadaRan2001 to 2006Enrolled41ConditionsBronchopulmonary DysplasiaArmsInhaled Beclomethasone Dipropionate Monohydrate
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kamini RaghuramDepartment of Paediatrics, University of Toronto, Toronto, ON, Canada.
Michael DunnDepartment of Paediatrics, University of Toronto, Toronto, ON, Canada.
Krista JangaardDepartment of Paediatrics, Izaak Walton Killam (IWK) Health Centre, Dalhousie University, Halifax, NS, Canada.
Maureen ReillyDepartment of Newborn Medicine and Developmental Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Elizabeth AsztalosDepartment of Paediatrics, University of Toronto, Toronto, ON, Canada.
Edmond KellyDepartment of Paediatrics, University of Toronto, Toronto, ON, Canada.
Michael VincerDepartment of Paediatrics, Izaak Walton Killam (IWK) Health Centre, Dalhousie University, Halifax, NS, Canada.
Vibhuti ShahDepartment of Paediatrics, University of Toronto, Toronto, ON, Canada. vibhuti.shah@sinaihealthsystem.ca.
University of Toronto · CAHealth Sciences Centre · CAIzaak Walton Killam Health Centre · CAMount Sinai Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInhaled corticosteroids (ICS) offer targeted treatment for bronchopulmonary dysplasia (BPD) with minimal systemic effects compared to systemic steroids. However, dosing of ICS in the management of infants at high-risk of developing BPD is not well established. The objective of this study was to determine an effective dose of ICS for the treatment of ventilator-dependent infants to facilitate extubation or reduce fractional inspired oxygen concentration.

methodsForty-one infants born at < 32 weeks gestational age (GA) or < 1250 g who were ventilator-dependent at 10-28 days postnatal age were included. A non-randomized dose-ranging trial was performed using aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP). Four dosing groups (200, 400, 600 and 800 μg twice daily for 1 week) with 11, 11, 10 and 9 infants in each group, respectively, were studied. The primary outcome was therapeutic efficacy (successful extubation or reduction in FiO

resultsThe median age at enrollment was 22 (10-28) postnatal days. The primary outcome, therapeutic efficacy as defined above, was not achieved in any group. However, there was a significant reduction in post-treatment FiO

conclusionsTherapeutic efficacy was not achieved with all studied doses of ICS. A significant reduction in oxygen requirements was noted in ventilator-dependent preterm infants at 10-28 days of age when given 800 μg of HFA-BDP bid. Larger randomized trials of ICS are required to determine efficacy for the management of infants at high-risk for development of BPD.

trial registrationThis clinical trial was registered retrospectively on clinicaltrials.gov. The registration number is NCT03503994 .

Indexed as

Administration, InhalationBronchopulmonary DysplasiaDrug Administration ScheduleDrug Delivery SystemsGlucocorticoidsHumansInfant, NewbornInfant, PrematureRespiration, ArtificialTreatment OutcomeVentilator WeaningGlucocorticoidsBronchopulmonary dysplasiaInfant-newbornInhaled steroidMetered dose inhalerPreterm

Identifiers

PMID29734948
PMCPMC5938808
OpenAlexW2807246610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.